

University Hospitals of Leicester NHS Trust

Research & Development Directorate

Performance in Delivering Research

1st October 2013 to 30th September 2014

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
06/MRE01/102	A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non small Cell Lung Carcinoma who have	10	31/03/2010	Closed - Follow Up Complete	N
07/MRE08/40	A double-blind randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen -Specific Cancer immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3 - positive Non -Small Cell Lung Cancer	12	31/05/2012	Closed - In Follow Up	N
08/H0606/29	Cleopatra: A PHASE III, Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Vs. Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer	5	07/07/2010	Closed - In Follow Up	N
08/H0502/132	BH21260- A randomised, controlled, open-label, multi-centre, parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment wit	9	14/10/2011	Closed - Follow Up Complete	Y
09/H0402/68	A Phase III Multicenter, Randomised, Parallel Group, Controlled, Double Blind Study to Investigate the Safety and Efficacy of Inhaled Mannitol over 12 Months in the Treatment of Bronchiectasis	5	30/12/2011	Closed - In Follow Up	Y

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
09/H0206/40	A Phase I/II Multi-centre Study of AZD8931 in Combination with Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Solid Tumours and in a selected population with Low HER2-expressing Locally Recurr	10	30/03/2011	Closed - In Follow Up	N
09/H0907/68	A 2x2 Factorial, Randomized, Multicenter, Single-Blind Evaluation of Intracoronary Abciximab Infusion and Aspiration Thrombectomy in Patients Undergoing Percutaneous Coronary Intervention for Anterior ST-Segment Elevation Myocardial Infarction	8	02/12/2011	Closed - In Follow Up	Y
09/H0405/44	A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer.	10	10/10/2011	Closed - In Follow Up	N
10/H0808/109	Evaluation of XIENCE PRIME™ or XIENCE V® versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization.	25	30/04/2014	Closed - In Follow Up	Y
08/H0304/110	Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes A 56 week randomised, double-blind, placebo-controlled, three armed parallel group, multi-centre, multinational trial with a 12 week observational follow-up period	5	21/09/2011	Closed - Follow Up Complete	Y
12/LO/0410	A DoubleBlind, Randomized, Parallel Group, MultiCentre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects with Overactive Bladder (OAB) Treated with Antimuscarinics and Dissatisfied due to Lack of Efficacy (BEYOND	6	07/12/2012	Closed - In Follow Up	N
11/EE/0536	The impact of LY2605541 versus insulin Glargine for Patients with Type 2 Diabetes Mellitus Advanced to Multiple injection Bolus insulin with insulin Lispro: a Double blind Randomized 26 week study the IMAGINE 4 Study	6	18/12/2012	Closed - In Follow Up	Y
12/EM/0089	A Single Blind, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of EVICEL® as an Adjunct to Gastrointestinal Anastomosis Techniques	10	31/10/2013	Closed - In Follow Up	N

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
12/NW/0209	QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study	5	18/07/2013	Closed - In Follow Up	Y
13/NI/0148	A phase II, randomised, doubleblind, placebocontrolled, multicentre trial to assess the oral corticosteroidsparing effect of lebrikizumab in patients with with severe corticosteroiddependant asthma	12	27/05/2018	Open	N/A
12/WM/0341	A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy In Patients with Clinically Evident Cardi	10	30/11/2014	Open	N/A
12/SC/0436	An open label, multi-center, efficacy and safety study of deferasirox in iron overloaded patients with non-transfusion dependent thalassemia (THETIS)	1	22/11/2013	Closed - In Follow Up	N
12/NW/0694	A 12-week randomized, open-label, active comparator period followed by a 12-week safety extension period to evaluate the safety and efficacy of Fesoterodine in subjects aged 6 to 16 years and >25 kg with symptoms of detrusor overactivity associated with a	2	31/12/2014	Open	N/A
12/LO/1285	A prospective, randomized, open label, parallel group, active controlled, multicenter study exploring the efficacy and safety of once daily oral rivaroxaban (BAY 597939) compared with that of dose adjusted oral vitamin K antagonists (VKA) for the preventi	13	30/09/2013	Closed - In Follow Up	Y
12/SC/0434	A randomised, multicentre, double blind, placebo controlled, crossover trial determining the efficacy of dry powder mannitol in improving lung function in subjects with Cystic Fibrosis aged six to seventeen years	4	31/12/2014	Open	N/A
12/LO/1697	BEL114674: A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy	1	25/10/2013	Closed - In Follow Up	N

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
13/LO/0291	Accu-Chek® Insight Insulin Pump EU Study: A European Multicenter Study to Evaluate the Accu-Chek® Insight Insulin Pump in Routine Practice	5	03/08/2014	Closed - In Follow Up	N
12/EM/0285	MEA115575: A Randomised, DoubleBlind, PlaceboControlled, ParallelGroup, Multicenter Study of Mepolizumab Adjunctive Therapy to Reduce Steroid Use in Subjects with Severe Refractory Asthma	6	02/07/2013	Closed - In Follow Up	Y
12/YH/0475	A PHASE Ib MULTICENTER DOSE-FINDING AND SAFETY STUDY OF GDC-0199 AND OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY OR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA	5	01/09/2014	Closed - In Follow Up	Y
12/NE/0314	Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children with Haemophilia B	1	28/02/2013	Closed - In Follow Up	Y
12/EM/0284	A multi-centre, open-label, long term safety study of mepolizumab in asthmatic subjects who participated in the MEA112997 trial	5	25/03/2013	Closed - In Follow Up	Y
12/WS/0230	NEFIGAN Trial: A Multicentre, Interventional treatment, Randomized, Double-Blind, Single Group Assignment Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon® in primary IgA nephropathy patients at risk of develop	4	20/12/2013	Closed - In Follow Up	Y
12/EM/0349	A multicenter, open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutations who have progressed on prior EGFR TKI treatment	3	11/06/2014	Closed - In Follow Up	Y
12/LO/1825	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma	2	01/01/2015	Open	N/A
12/EM/0308	A multicenter, double-blind and open label, 2 year extension study of subcutaneous secukinumab in prefilled syringes, assessing long-term safety, tolerability and efficacy in subjects with moderate to severe chronic plaque-type psoriasis treated with eith	2	28/02/2013	Closed - In Follow Up	Y

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
12/EM/0395	A randomised, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Diseases	30	27/02/2014	Closed - In Follow Up	Y
13/LO/0418	A multi-centre, randomised, placebo controlled double blind, two armed, parallel group study to evaluate efficacy and safety of IV Sildenafil in the treatment of neonates persistent pulmonary hypertension of the newborn (PPHN) or hypoxic respiratory failu	3	31/03/2014	Closed - In Follow Up	N
12/SC/0527	A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With First Episode of Acute Optic Neuritis	2	30/01/2014	Closed - In Follow Up	N
13/SC/0092	A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of siponimod (BAF312) in patients with secondary progressive multiple sclerosis	6	29/05/2014	Open	N/A
12/LO/1590	A phase III randomised, partially double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended population of treatment naïve patients that includes those i	1	23/03/2013	Closed - In Follow Up	Y
12/SW/0318	A double blind, double dummy, randomised, multi-centre study to assess the tolerability and efficacy profile of vildagliptin compared to gliclazide as dual therapy with metformin in Muslim patients with type 2 diabetes fasting during Ramadan	5	14/05/2013	Closed - In Follow Up	N
13/LO/0021	Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment (PRESENT)	10	31/01/2015	Open	N/A

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
13/ES/0005	A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care versus Placebo Plus Best Supportive Care in Subjects with Red Blood Cell Transfusion-dependent Anemia and Thrombocyte	4	15/06/2015	Open	N/A
13/NW/0006	A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas	3	31/03/2015	Open	N/A
13/LO/0578	A randomized, double blind, placebo controlled, multi-centre study to assess the pharmacodynamics, pharmacokinetics, safety and tolerability of BYM338 in chronic obstructive pulmonary disease patients with cachexia	3	18/06/2014	Closed - In Follow Up	N
12HAEM15	Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes	5	22/11/2013	Closed - In Follow Up	N
13/EM/0149	Multicenter open-label study to evaluate efficacy of gadobutrol-enhanced cardiac magnetic resonance imaging (CMRI) for detection of significant coronary artery disease (CAD) in subjects with known or suspected CAD by a blinded image analysis	15	12/02/2015	Open	N/A
09/H0606/12	ABBOTT - A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination with Temozolomide Versus Temozolomide Alone in Subjects with Metastatic Melanoma.	5	05/01/2010	Closed - In Follow Up	N
12/LO/1950	A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma	8	28/11/2014	Open	N/A
13/NW/0003	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE-3 STUDY TO ASSESS THE SAFETY AND EFFICACY OF ART-123 IN SUBJECTS WITH SEVERE SEPSIS AND COAGULOPATHY	6	01/03/2015	Open	N/A

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
13/SC/0073	A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects with Heart Failure and Left Ventricular Systolic Dysfunction	6	31/08/2013	Open	N/A
13/LO/0033	A Phase II, randomized study of paclitaxel with GDC-0941 versus paclitaxel with placebo in patients with locally recurrent or metastatic breast cancer	2	01/07/2014	Closed - In Follow Up	Y
13/NE/0080	A randomized, open-label, active-controlled, 3-arm parallel-group, 26-week study comparing the efficacy and safety of lixisenatide to that of insulin glulisine once daily and insulin glulisine three times daily in patients with Type 2 diabetes insufficient	3	02/06/2014	Closed - In Follow Up	N
13/LO/0105	Open-label, single-arm, phase IV, multicentre trial to explore the immunogenicity of the liquid formulation of Saizen® in subjects with growth hormone deficiency (GHD) of adult onset	4	01/02/2015	Open	N/A
13/NE/0001	NN7088-3885 (Pathfinder 5): A multinational, open-label, non-controlled trial on safety, efficacy and pharmacokinetics of NNC 0129-0000-1003 in previously treated paediatric patients with severe haemophilia A	1	07/02/2014	Closed - In Follow Up	Y
13/EM/0084	A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients with Severe Hemophilia A	1	31/10/2013	Closed - In Follow Up	Y
13/YH/0003	An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma with 17p Deletion	1	31/08/2013	Closed - In Follow Up	Y
13/SC/0010	A Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety and Efficacy of 28 Day Oral Administration of BAY 85-8501 in Patients with non-Cystic Fibrosis Bronchiectasis	3	10/04/2014	Closed - In Follow Up	Y

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
13/LO/0219	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER)	5	01/12/2016	Open	N/A
13/EM/0460	A RANDOMIZED, MULTICENTER, OPEN-LABEL TRIAL COMPARING CHEMOTHERAPY PLUS TRASTUZUMAB PLUS PERTUZUMAB VERSUS CHEMOTHERAPY PLUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2 POSITIVE PRIMARY BREAST CANCER	7	14/02/2016	Open	N/A
13/SC/0102	A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Squamous Histology Non-Small Cell Lung Cancer	3	16/12/2014	Open	N/A
13/LO/0326	A Randomized, Phase 3 Study of Ganetespib in Combination with Docetaxel versus Docetaxel Alone in Patients with Advanced Non-Small-Cell Lung Adenocarcinoma	8	02/03/2015	Open	N/A
13/EM/0097	MEA115661: A multi-centre, open-label, long-term safety study of mepolizumab in asthmatic subjects who participated in the MEA115588 or MEA115575 trials	8	11/12/2013	Closed - In Follow Up	N
13/YH/0140	Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with Chronic Heart Failure with Preserved left ventricular Ejection Fraction An 8-month, randomised double-blind, placebo controlled, int	6	15/06/2015	Open	N/A
13/WA/0084	A Randomised, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus	7	10/10/2014	Open	N/A
13/WM/0114	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma	5	30/10/2014	Open	N/A

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
13/NI/0044	A STUDY TO MEASURE SERUM PERIOSTIN, ASTHMA RELATED BIOMARKERS AND RESPONSE TO PREDNISOLONE IN ADULT AND ADOLESCENT PATIENTS WITH SEVERE ORAL CORTICOSTEROID DEPENDENT ASTHMA	6	28/02/2014	Closed - In Follow Up	N
13/LO/0491	A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Multi-centre Study of POL6326, a CXCR4 Antagonist, in Patients with Large Reperused ST-Elevation Myocardial Infarction	5	30/11/2014	Open	N/A
13/SS/0072	Patient-reported outcomes of Brimonidine Tartrate 0.5% gel for treatment of severe facial erythema of rosacea	4	08/11/2013	Closed - In Follow Up	Y
13/EM/0251	A multicenter, randomized, double-blind, placebo- controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients	6	21/12/2015	Open	N/A
13/EM/0230	A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS 6063 in Subjects with Malignant Pleural Mesothelioma	10	01/08/2015	Open	N/A
13/NW/0464	A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in Subjects with Acute-on-Chronic Liver Failure	2	31/07/2014	Open	N/A
13/SC/0384	A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma	2	30/03/2015	Open	N/A
13/EM/0284	A phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum double	10	29/12/2014	Open	N/A
13/EE/0241	Secukinumab In patients with moderate to severe active, chronic plaque psoriasis who have failed on TNFa antaGoNists: A clinical Trial EvalUating Treatment RESULTS (SIGNATURE)	2	09/10/2014	Open	N/A

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
13/EE/0377	A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids	3	31/08/2014	Open	N/A
13/NW/0692	A multicenter, international, randomized, parallel group, double blind, placebo-controlled Cardiovascular Safety & Renal Microvascular outcome with LINagliptin, 5 mg once daily in patients with type	10	31/03/2016	Open	N/A
13/SC/0490	A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma who are on inhaled corticosteroids and second controller medication.	5	31/08/2018	Open	N/A
13/EE/0247	A Phase 2a, 4-Week Treatment Period, Randomized, Double-Blind, Parallel Group, PA Phase 2a, 4-Week Treatment Period, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of Inhal	6	13/06/2014	Closed - In Follow Up	Y
13/WM/0451	A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG337 in subjects with MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma or Other MET Amplified Solid Tumors	3	22/05/2015	Open	N/A
13/EE/0326	REVACEPT, AN INHIBITOR OF PLATELET ADHESION IN SYMPTOMATIC CAROTID STENOSIS: A PHASE II, MULTICENTRE; RANDOMISED, DOSE-FINDING, DOUBLE-BLIND AND PLACEBO-CONTROLLED SUPERIORITY STUDY WITH PARALLEL GROUPS	6	30/06/2015	Open	N/A
13/NE/0344	A Phase 3, Randomized, Double-Blind, Placebo Controlled, 26-Week Multicenter Study with a 26-Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic	7	16/01/2015	Open	N/A
13/EM/0414	A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Therapy.	3	31/07/2014	Closed - In Follow Up	Y

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
14/EM/0101	An exploratory, 12 week, randomised, partially double-blinded, placebo-controlled, parallel group trial to explore the effects of once daily treatments of orally inhaled tiotropium + olodaterol fixed dose combination or tiotropium (both delivered by the R	3	20/10/2014	Open	N/A
14/SC/0065	A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus	8	15/06/2015	Open	N/A
14/SC/0104	A Phase 2b, Randomized, Double blind, Placebo-controlled, Parallel group, Multicentre, Dose finding Study to evaluate the Efficiency, Safety and Tolerability of AZDI1722 to Treat Hyperphosphataemia in End-Stage Renal Disease on Haemodialysis(ESRD-HD)	5	31/10/2014	Open	N/A
09/H0605/87	TECOS - A Randomised, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycaemic Control on Mono or Dual Combination Oral Antihyperglycaemic The	35	31/05/2012	Closed - In Follow Up	Y
14/SC/0185	A Randomized, Double-Blind Trial Comparing the Effect of Dulaglutide 1.5 mg with Placebo on Glycemic Control in Patients with Type 2 Diabetes on Basal Insulin Glargine (AWARD-9: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 9)	5	31/03/2015	Open	N/A
09/H0706/22	Aliskiren vs enalapril in chronic heart failure	4	14/12/2013	Closed - Follow Up Complete	Y
09/H0402/101	A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus (The CANVAS Trial: CANagliflozin CardioVascular Assessment Study)	8	31/01/2011	Closed - In Follow Up	Y
09/H0206/46	A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination with Anastrozole, Compared to Anastrozole alone, in Post-menopausal Women With Hormone Receptor-positive, Endocrine Th	4	17/05/2012	Closed - In Follow Up	Y

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
09/H0605/113	Effects of ivabradine in patients with stable coronary artery disease without clinical heart failure. A randomised double-blind placebo-controlled international multicentre study. Sub-Study protocol on QUALITY OF LIFE attached to CL3-16257-083 study	10	30/04/2012	Closed - In Follow Up	N
09/H0802/125	An OpenLabel, MultiCenter, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Zanamivir in the Treatment of Hospitalised Adult, Adolescent and Paediatric Subjects with Confirmed Influenza Infection	1	27/01/2017	Open	N/A
10/H0405/23	A prospective, multi-center, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI) with either drug-eluting stent	22	31/05/2011	Closed - In Follow Up	Y
09/H0406/110	A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction (CLCZ696B2	6	11/10/2012	Closed - In Follow Up	Y
10/H0402/36	A Phase III, randomized, comparative, open-label study of intravenous Iron Isomaltoside 1000 (Monofer®) administered by infusions or repeated bolus injections in comparison with oral Iron Sulphate in subjects with non-dialysis dependent chronic kidney dis	2	28/02/2014	Closed - In Follow Up	Y
10/H0406/34	A randomised, 3 arm, multi-centre, phase 3 study to evaluate the efficacy and the safety of T-DM1 combined with Pertuzumab or T-DM1 combined with Pertuzumab-placebo (blinded for Pertuzumab), versus the combination of trastuzumab plus taxane, as first-line	5	29/02/2012	Closed - In Follow Up	Y

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
10/MREC00/61	An Open Label, Multicenter, randomized, phase III study to investigate the efficacy and safety of Bendamustine compared with Bendamustine + RO5072759 (GA101) in patients with Rituximab-refractory, indolent Non-Hodgkin's Lymphoma)	6	01/08/2014	Open	N/A
11/H0402/4	A Phase 3, Multicenter, Randomized, DoubleBlind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination with Gemcitabine as Firstline Therapy for Metastatic Adenocarcinoma of the Pancreas	5	15/08/2012	Closed - In Follow Up	Y
11/NE/0124	A Phase III, Randomized, Comparative, Openlabel Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison with Intravenous Iron Sucrose in Subjects with Stage 5 Chronic	10	09/08/2013	Closed - In Follow Up	Y
11/LO/0608	A Randomized, Double Blind, Phase II Efficacy and Safety Study of MDV3100 (ASP9785) vs. Bicalutamide in Castrate Men with Metastatic Prostate Cancer	4	14/06/2013	Closed - In Follow Up	N
11/NW/0298	A multicenter, Phase III, open-label, randomized study in previously untreated patients with advanced indolent non-Hodgkin's Lymphoma comparing GA101 (Ro5072759) plus chemotherapy with rituximab plus chemotherapy followed by GA101 or rituximab maintenance	5	17/01/2014	Closed - In Follow Up	Y
11/LO/0448	A randomized, doubleblind, placebocontrolled, multipledose, exploratory proof of concept study to assess the safety, tolerability, efficacy, pharmacodynamics and pharmacokinetics of QAX576 in patients with rapidly progressive idiopathic pulmonary fibrosis.	5	27/09/2012	Closed - In Follow Up	Y
11/NW/0472	Phase III, open-label, multicentre, randomised trial to establish safety and efficacy of an EGF cancer vaccine in inoperable, late stage (IIIb/IV) NSCLC patients eligible to receive standard treatment and supportive care.	6	27/11/2013	Closed - In Follow Up	Y
11/SC/0234	A randomised, double-blind, multicentre study of subcutaneous secukinumab, assessing Psoriasis Area and Severity Index (PASI) response and maintenance of response in subjects with moderate to severe chronic plaque-type psoriasis on either a fixed dose reg	5	08/02/2012	Closed - In Follow Up	N

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
11/LO/0419	An open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathway	2	31/10/2013	Closed - In Follow Up	N
11/LO/0954	LUXHead & Neck 2; A randomised, doubleblind, placebo controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients with stage III, IVa, or IVb locoregiona	5	01/05/2017	Open	N/A
11/EE/0291	A Phase 3, Randomised, Open Label Trial of Lenalidomide/ dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma	7	26/09/2012	Closed - In Follow Up	N
11/LO/0548	An open-label, randomized, multi-center, Phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor Therapies)	3	10/08/2012	Closed - In Follow Up	N
11/YH/0121	A phase II, randomized double-blind study of efficacy and safety of two dose levels of LDE225 in patients with locally advanced or metastatic basal cell carcinoma	2	11/01/2013	Closed - In Follow Up	Y
11/AL/0327	A Phase 2, Multicentre, randomised, double-blind, placebo controlled study of the safety, clinical activity and pharmacokinetics of Bosutinib (PF-05208763) versus placebo in subjects with autosomal dominant polycystic kidney disease (ADPKD)	5	25/05/2012	Closed - In Follow Up	N
11/LO/1728	Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 years. A randomised, double-blind, multicentre, placebo controlled, pha	5	15/02/2013	Closed - In Follow Up	N
11/EM/0180	A clinical outcomes study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) in comparison with etanercept (ETA) on the rate of cardiovascular events in patients with moderate to severe rheumatoid arthritis (RA)	6	13/03/2013	Closed - In Follow Up	N

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
11/EE/0311	A randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression with observation only in patients with relapsed or refractory, indolent nonHodgkin's lymphoma who completed and responded to rituximabbased immunochem	5	31/03/2014	Closed - In Follow Up	Y
11/EM/0270	A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults with Uncontrolled, Severe Asthma	4	14/05/2012	Closed - In Follow Up	N
11/LO/1869	A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF PF00299804 VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NONSMALL CELL LUNG CANCER FOLLOWING PROGRESSION AFTER, OR INTOLERANCE TO, AT LEAST ONE PRIOR CHEMOTHERAPY	5	21/02/2013	Closed - In Follow Up	Y
11/LO/1408	ABSORB II RANDOMIZED CONTROLLED TRIAL: A clinical evaluation to compare the safety, efficacy and performance of ABSORB TM everolimus eluting bioresorbable vascular scaffold system against XIENCE PRIME TM everolimus eluting coronary stent system in the tre	10	04/06/2013	Closed - In Follow Up	Y
11/SC/0438	REPLACE (Randomised evaluation of fibrinogen versus placebo in complex cardiovascular surgery): a prospective, multinational, multicenter, randomised, double-blind, placebo-controlled, phase III study for the use of Fibrinogen Concentrate (Human) (FCH) in	7	31/07/2014	Closed - In Follow Up	N
12/SC/0098	A Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma	10	22/07/2014	Closed - In Follow Up	N
11/SS/0054	Clinical Trial of the SonRtip Lead and Automiatic AVV Optimization Algorithm in the Paradym RF SonR CRT-D (RESPOND CRT)	10	31/12/2014	Open	N/A
11/NE/0375	A Multicentre, Double-Blind, Placebo-Controlled, Adaptive Pivotal Study of the Efficacy and Safety of Oral BC1036 in the Management of Cough	10	12/07/2013	Closed - In Follow Up	Y

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
12/SC/0035	A 6-month safety and benefit study of inhaled fluticasone propionate/ salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 paediatric subjects 4-11 years old with persistent asthma.	6	31/08/2015	Open	N/A
12/SC/0025	A 24-month, phase IIb, open-label, randomised, active controlled, 3-arm , multicenter study assessing the efficacy and safety of an individualised, stabilization-criteria-driven PRN dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as	10	31/05/2013	Closed - In Follow Up	N
12/SC/0024	A 24month, phase IIIb, openlabel, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteriadriven PRN dosing regimen with 0.5mg ranibizumab intravitreal injections applied as monotherapy in patients with	10	11/03/2013	Closed - In Follow Up	N
11/WA/0309	A Comparison of LY2605541 versus Insulin Glargine as Basal Insulin Treatment in Combination with Oral AntiHyperglycemia Medications in Insulin Naive Patients with Type 2 Diabetes Mellitus: A DoubleBlind, Randomized Study: The IMAGINE 2 Study.	6	27/11/2012	Closed - In Follow Up	N
11/SC/0485	The Impact of LY2605541 versus Insulin Glargine for Patients with Type 1 Diabetes Mellitus Treated with Preprandial Insulin Lispro: a Double Blind, Randomized Week Study: The IMAGINE 3 Study	7	26/10/2012	Closed - In Follow Up	Y
12/LO/0098	CAIN457 to assess safety tolerability efficacy & PK in asthma	5	28/02/2014	Open	N/A
12/EE/0005	A multicentre, double blind, randomised controlled Clinical Investigation to validate the EPS1 device as a treatment for stroke induced dysphagia. A Study of Swallowing Treatment using Electrical Pharyngeal Stimulation (STEPS Study)	3	30/06/2014	Closed - In Follow Up	Y
11/EM/0402	A double-blind, placebo-controlled, study examining the effect of orally administered QAW039 (225 mg BID) on sputum eosinophil levels and other efficacy outcomes in patients with sputum eosinophilia and persistent asthma	30	31/01/2013	Closed - In Follow Up	Y
12/SC/0150	Switching from Ticagrelor to prasugrel in subjects with stable coronary artery disease: 2nd switching antiplatelet agents SWAP2	3	24/01/2013	Closed - In Follow Up	Y

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
12/EM/0018	A randomised, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP.	10	28/01/2014	Closed - In Follow Up	N
12/NW/0082	A randomised, double-blind, placebo-controlled, parallel group study to determine the effect of 12 weeks treatment of orally inhaled tiotropium+olodaterol fixed dose combination (2.5/5 mg, 5/5 mg) delivered by the Respimat Inhaler, on exercise endurance t	5	26/04/2013	Closed - In Follow Up	Y
12/WM/0039	INOVAEHF: INcrease Of VAgal TonE in chronic Heart Failure.	10	31/12/2014	Open	N/A
12/SC/0121	Liraglutide in Type 2 Diabetes and Moderate Renal Impairment	6	22/02/2013	Closed - In Follow Up	N
14/LO/0673	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant	3	28/02/2017	Open	N/A
12/LO/1125	Occlutech percutaneous PFO closure:Safety and Efficacy OPPOSE Registry	15	31/12/2014	Open	N/A
13/LO/1517	Phase 3, Randomized, Open Label, Active-Controlled Study to Evaluate the Efficacy and Safety of FG4592 in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis	4	04/05/2015	Open	N/A
13/SC/0616	A Phase II, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals' investigational vaccine GSK2838504A, when administered intramuscularly according to a 0, 2 month s	10	29/07/2016	Open	N/A
14/LO/1050	A Multicenter Phase 3 Randomized Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia.	7	05/07/2015	Open	N/A
14/ES/0001	Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment with Ertugliflozin (MK-8835/PF-04971729) in Participants with Type 2 Diabetes Mellitus and Established Vascular Disease	7	05/05/2015	Open	N/A

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
14/EE/0102	A prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study comparing edoxaban (DU-176b) with enoxaparin/warfarin followed by warfarin alone in subjects undergoing planned electrical cardioversion of nonvalvular atrial	9	31/12/2015	Open	N/A
14/YH/0086	RESPOND: Repositionable Lotus Valve System – Post Market Evaluation of Real World Clinical Outcomes	15	11/12/2020	Open	N/A
14/YH/0141	nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation	25	01/10/2018	Open	N/A
06/Q2404/56	A Double-blind, Randomised, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of Darbepoetin alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction and Anaemia	5	30/11/2011	Closed - Follow Up Complete	Y
06/MRE01/39	Phase III, randomised, double blind, stratified comparative, placebo controlled, parallel group, multicentre study to assess the effect of deep subcutaneous injections of lanreotide Autogel 120 mg administered every 28 days on tumour progression free surv	4	31/05/2011	Closed - Follow Up Complete	N
07/MRE04/23	AVEX: A randomised, open-label Phase III study to assess efficacy and safety of bevacizumab in combination with capecitabine as first line treatment for elderly patients with metastatic colorectal cancer.	9	01/12/2011	Closed - Follow Up Complete	N
07/S0501/91	An open label, single arm, multi centre phase II trial with ofatumumab in patients with relapsed Diffuse Large B Cell Lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant	5	31/12/2009	Closed - In Follow Up	N
07/H1307/213	Comparison of the efficacy and safety of a strategy of pre-hospital fibrinolytic treatment with tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 6-24 hours or rescue coronary intervention versus a strate	6	27/07/2012	Closed - Follow Up Complete	Y

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
08/H1107/58	A phase II uncontrolled study of BAY 73-4506 (DAST) in previously untreated patients with metastatic or unresectable renal cell cancer (RCC).	5	30/01/2008	Closed - In Follow Up	N
08/H0405/18	A double blind, randomised, multiple dose, Phase III, multicentre study of Alpharadin in the treatment of patients with hormone refractory prostate cancer with skeletal metastases.	5	28/02/2011	Closed - Follow Up Complete	Y
08/H0206/34	A Multicentre, Double-Blind 3-Arm, Phase 1b/2 Study in Subjects with Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Efficacy of First-line Treatment with Epirubicin Cisplatin and	7	31/07/2010	Closed - In Follow Up	N
08/H0406/171	A Phase 1/2a study evaluating the safety pharmacokinetics and efficacy of ABT-263 in subjects with relapsed or refractory chronic lymphocytic leukaemia.	10	31/10/2010	Closed - In Follow Up	N
08/MRE00/93	A single-arm, international, multi-centre trial investigating the efficacy and safety of atumumab re-treatment and maintenance treatment in patients with B-cell chronic lymphocytic leukemia who progressed following response or stable disease after of atum	10	30/11/2009	Closed - In Follow Up	N
08//H0703/132	An open-label, multi-centre, randomised, phase Ib study to investigate the safety and efficacy of RO5072759 given in combination with CHOP or FC chemotherapy in patients with CD20+ relapsed/refractory B-cell follicular non-Hodgkin's lymphoma.	2	30/09/2011	Closed - In Follow Up	Y
09/H0406/5	A phase IA/II multi-centre open label study of HCD 122 administered once weekly for four weeks in adult patients with advanced non Hodgkins or Hodgkins lymphoma who have progressed after at least two prior therapies	10	30/09/2010	Closed - In Follow Up	N
09/H0402/71	A phase I multicentre, open label, dose escalation study of oral LDE225 in patients with advanced solid tumours.	5	30/09/2011	Closed - In Follow Up	Y
09/H0402/92	A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer.	10	31/08/2011	Closed - In Follow Up	Y

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
09-WSE04-55	An open-label, multi centre, three arm randomised, phase III study to investigate the efficacy and safety of R05072759 + chlorambucil (GClb), rituximab and chlorambucil (RClb) or chlorambucil (Clb) alone in previously untreated CLL patients with co-morbid	5	01/06/2012	Closed - In Follow Up	Y
09/H0803/138	Prostate Cancer Antigen-3 (PCA-3) and TMPRSS2-ERG (T2-ERG) Score changes during initiation of Androgen Deprivation Therapy (ADT) with triptorelin (22.5mg) in patients with advanced prostate cancer (PCa): A phase III, single arm multicentre study	6	15/02/2011	Closed - Follow Up Complete	Y
09/H1008/116	A Phase II International Multi-Centre randomised Open Label Study of oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women with Advanced or Recurrent Endometrial Cancer.	2	30/06/2011	Closed - Follow Up Complete	Y
10/H0402/33	CAVALIER: Perceval S valve clinical trial for extended CE mark	15	30/03/2012	Closed - In Follow Up	Y
09/H0903/51	An Extension Treatment Protocol for Subjects who have participated in a Phase 3 study of Tivozanib vs. Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301)	5	31/12/2012	Closed - In Follow Up	N
10/H0703/56	An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer	5	31/10/2012	Closed - In Follow Up	N
10/H0505/78	A Phase Ib/II, multi enter, open-label study to evaluate the efficacy of AUY922 in combination with Trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer, that has progressed after or during at least one trastuzumab-conta	4	01/06/2012	Closed - Follow Up Complete	Y
10/MRA00/84	A phase I, multicenter, open-label dose escalation study of LDK378, administered orally in adult patients with tumors characterized by genetic abnormalities in anaplastic lymphoma kinase(ALK)	2	26/07/2013	Closed - In Follow Up	Y

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
10/H0406/85	PATIENT MATCHED INSTRUMENTATION VS. STANDARD INSTRUMENTATION: A RANDOMIZED CLINICAL TRIAL COMPARING POSTOPERATIVE AXIAL ALIGNMENT and COMPONENT POSITION	70	30/09/2012	Closed - Follow Up Complete	N
09/H1306/82	A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency	1	31/12/2011	Closed - Follow Up Complete	Y
10/H0406/90	A Randomized, Double-Blind, Placebo-controlled Phase 2 Study of Maintenance OSI-906 plus Erlotinib (Tarceva®), or Erlotinib plus Placebo in Patients with Nonprogression Following Four Cycles of 1st-line Platinum-based Chemotherapy for Advanced NSCLC	3	20/02/2013	Closed - Follow Up Complete	Y
10/H0806/106	An open Phase I Study of immunization with the recNY-ESO-1 + AS15 Antigen-Specific Cancer Immunotherapeutic in patients with NY-ESO-1-positive unresectable and progressive metastatic cutaneous melanoma	4	01/10/2012	Closed - In Follow Up	N
08/H0502/133	BH21260- A randomised, controlled, open-label, multi-centre, parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment wit	100	31/03/2012	Closed - In Follow Up	N
11/LO/0553	Effect of late sodium current inhibition on MRI measured diastolic dysfunction and myocardial perfusion reserve in aortic stenosis - a proof of concept study.	20	20/03/2012	Closed - Follow Up Complete	Y
11/EM/0225	A PHASE III, MULTICENTER, RANDOMISED TRIAL COMPARING THE EFFICACY OF GA101 IN COMBINATION WITH CHOP (G-CHOP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH CD20-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)	5	01/05/2013	Open	N/A
11/NI/0147	Assessment of the 23mm St Jude Medical Portico transcatheter Aortic Valve Implant (TAVI) and the SJM TAVI Transfemoral Delivery System (Portico 23-TF EU)	12	30/04/2012	Open	N/A

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
11/LO/1271	Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer - Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients with NSCLC-C	14	01/07/2012	Closed - In Follow Up	N
11/LO/1272	Anamorelin HCl in the Treatment of NonSmall Cell Lung Cancer Cachexia (NSCLCC): An Extension Study	14	01/07/2012	Closed - In Follow Up	N
11/EE/0452	Main Trial: A 16-week, randomised, placebo-controlled, double blind, and parallel group trial to assess the anti-inflammatory effects of Roflumilast in chronic obstructive pulmonary disease Sub-Trial: The Interaction Between Changes in the Lung Microbiot	15	31/12/2013	Closed - Follow Up Complete	N
11/LO/0054	NGR015: Randomized double-blind phase III study of NGR-hTNF plus best investigator's choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM)	15	01/12/2012	Closed - In Follow Up	N
12/NE/0016	A randomized, open-label, multicenter Phase IIIb study comparing two trastuzumab dosing regimens, each in combination with cisplatin/capecitabine chemotherapy, as first-line therapy in patients with HER2-positive metastatic gastric or gastro-esophageal iu	4	31/03/2017	Closed - Follow Up Complete	N
12/EM/0051	Phase I/II dose-escalation study of oral administration of the Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in Hodgkin's Disease, non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia	10	31/10/2013	Open	N/A
11/LO/1810	A prospective, single arm feasibility study to evaluate the safety and performance of the SMT Embolic Deflection Device in patients undergoing Transcatheter Aortic Valve Replacement (TAVR).	10	31/05/2012	Closed - Follow Up Complete	N
11/SC/0499	A UK openlabel, multicentre, phase II exploratory study of INC424 for patients with primary myelofibrosis (PMF) or post polycythaemia myelofibrosis (PPV MF) or postessential thrombocythaemia myelofibrosis (PETMF)	3	30/11/2012	Closed - In Follow Up	Y

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
11/AL/0393	A Randomized, Phase IIB/III Study of Ganetespib (STA-9090) in Combination with Docetaxel Versus Docetaxel Alone in Subjects with Stage IIIb or IV Non-Small-Cell Lung Cancer	20	01/06/2013	Closed - In Follow Up	N
12/LO/0806	A Multicenter, Single arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Afibercept in Patients with Metastatic Colorectal Cancer (mCRC) Previously Treated with an Oxaliplatin-Containing Regimen	5	30/04/2013	Closed - In Follow Up	Y
12-LO-0928	MASERATI 100 A prospective, Multicenter, postmarket, single Arm observational study to collect clinical outcome data on the use of Permacol™ Collagen Paste in the treatment of anorectal fistulas	10	28/02/2013	Open	N/A
12/SC/0139	A Phase III Prospective, Two-cohort, Non-randomized, Multi-centre, Multi-national, Open Label Study to Assess the Safety of Assisted- and Self-administered Subcutaneous Trastuzumab as Adjuvant Therapy in Patients with Operable HER2-positive Early Breast C	10	23/09/2016	Open	N/A
12/EM/0204	An open-label, multi-centre, non-randomised phase I dose-escalation study to investigate the safety and tolerability of ONO-4059 given as monotherapy in patients with relapsed/refractory Non-Hodgkin's lymphoma (NHL) and relapsed/refractory chronic lymphoc	7	15/07/2015	Open	N/A
12/NW/0241	A Randomised, Phase III, Multicentre, DoubleBlind, PlaceboControlled Study Evaluating the Efficacy and Safety of MetMAB in Combination with Tarceva® (Erlotinib) in Patients with MetDiagnosticPositive NonSmall Cell Lung Cancer (NSCLC) who have received stan	5	20/08/2013	Closed - Follow Up Complete	N
12/NW/0242	An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy	15	01/03/2013	Closed - In Follow Up	N

Performance in Initiating and Delivering Clinical Research

REC Reference Number	Name of Trial	Recruitment Target	Date recruitment closed	Trial Status	Target met?
12/NE/0009	A Phase II, Double-Blind, Placebo Controlled, Randomized Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab with and without GDC-0941 in patients with Previously Untreated Advanced or Recurrent Non-Sm	5	31/03/2015	Open	N/A
12/LO/1313	ROX CONTROL HTN Study: A Prospective, Randomized, Open-Label, Multicenter Study to Evaluate the ROX Coupler in Patients with Resistant Hypertension	20	31/12/2013	Open	N/A
12/EM/0206	An open label non-randomized phase 2 study evaluating SAR3419, an anti-CD19 antibody – maytansine conjugate, administered as single agent by intravenous infusion to patients with relapsed or refractory CD19+ diffuse large B cell lymphoma	2	30/06/2013	Open	N/A
12/NE/0333	A multicentre, open label, early stopping design, proof of concept study with tasquinimod in treating patients with advanced or metastatic hepatocellular, ovarian, renal cell and gastric carcinomas.	10	01/11/2015	Closed - In Follow Up	N
13/E5/0088	A Multicentre, double blind, randomized, parallel group, placebo-controlled study to evaluate the effects of intravenous serelaxin infusion on micro - and macro-vascular function in subjects with coronary artery disease.	30	30/06/2015	Open	N/A
13/LO/1766	A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indicati	3		Open	N/A
13/EM/0476	ABSORB UK Registry A postmarket registry of patients with de novo lesions in previously untreated vessels treated with Absorb BVS	30		Open	N/A

For data queries please contact Khurram Memon on 0116 258 4573 or Khurram.Memon@uhl-tr.nhs.uk